Cefaly develops a non-invasive neuromodulation device designed to treat and prevent migraine through external trigeminal nerve stimulation. The company’s technology is delivered via a wearable device placed on the forehead, enabling stimulation without surgical intervention. Its product is cleared for over-the-counter use, positioning it for direct access by patients. Cefaly operates within regulated medical device frameworks rather than consumer wellness.

The technology delivers controlled electrical stimulation to branches of the trigeminal nerve through the skin. By modulating trigeminal nerve activity, the system aims to influence neural pathways involved in migraine generation and pain processing. The device supports both acute treatment during migraine attacks and preventive use through regular stimulation sessions. This approach avoids pharmacological intervention while providing a repeatable neuromodulation therapy.

Cefaly targets individuals with migraine seeking non-drug treatment options for symptom relief and prevention. The device is intended for home use and can be integrated into routine migraine management without clinical supervision for each session. Its positioning reflects broader interest in accessible, non-invasive neuromodulation therapies for chronic neurological conditions.